engineered the first T cells secreting BiTEs that were designed to enable a targeted immune response against the ephrin type-A receptor 2 (EphA2), which is expressed on glioblastoma, breast, prostate, and lung tumor cells. This evidence concerns the gene EPHA2 and glioblastoma.